indication

Pediatric

Competitive landscape projected to Lumateperone (Caplyta)’s launch window

as of 2026-07-01
Competitive set
1
1 approved · 0 pipeline

Projection timeline

actual past → guided future · protection walls overlaid
16 events
2020
2022
2024
2026
2028
2030
today
Lumateperone (Caplyta) launch window
guided / estimated ↑
actual ↓
focal / guidedapprovallabel expansiontrial readoutcongressnclustered events (click to expand)guided (dashed = directional)competitor patent cliff

Competitive set

resolved drugs with trials in this indication
drugfocal
Lumateperone (Caplyta)
US-approved 2019 · CAPLYTA
Phase 11 trial
OwnerIntra-Cellular Therapies, Inc.
Protection2040

Market size

prevalence as a range, not a number